Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain

Lung Cancer ◽  
2007 ◽  
Vol 57 (3) ◽  
pp. 359-364 ◽  
Author(s):  
Chi Wu ◽  
Yun Long Li ◽  
Zhao Meng Wang ◽  
Zhang Li ◽  
Tong Xiao Zhang ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Palliative Therapy ◽  
The Brain

scholarly journals Clinical experience of effective use of palliative targeted therapy in a patient with EGFR-negative lung adenocarcinoma

2019 ◽  
pp. 142-145
Author(s):  
L. M. Kogonia ◽  
E. V. Markarova ◽  
G. A. Stashuk ◽  
M. M. Byakhova ◽  
M. M. Akhmetov
Keyword(s):  
Quality Of Life ◽  
Targeted Therapy ◽  
Lung Adenocarcinoma ◽  
Clinical Experience ◽  
Positive Response ◽  
Target Therapy ◽  
Palliative Therapy ◽  
Response To Therapy ◽  
Effective Use

The article describes the experience in effective use of the second-generation EGFR II blocker in palliative target therapy of EGFRnegative lung adenocarcinoma. The use of afatinib in the fifth-line palliative therapy of EGFR-negative lung adenocarcinoma allowed us to achieve a significant positive response to therapy in the lungs and improve the patient’s quality of life.

scholarly journals Effects of bioavailable phenolic compounds from Ilex paraguariensis on the brain of mice with lung adenocarcinoma

2019 ◽  
Vol 33 (4) ◽  
pp. 1142-1149 ◽  
Author(s):  
María C. Cittadini ◽  
Gastón Repossi ◽  
Claudia Albrecht ◽  
Romina Di Paola Naranjo ◽  
Agustín R. Miranda ◽  
...  
Keyword(s):  
Phenolic Compounds ◽  
Lung Adenocarcinoma ◽  
Ilex Paraguariensis ◽  
The Brain

scholarly journals Gene Expression Profile in Primary Tumor Is Associated with Brain-Tropism of Metastasis from Lung Adenocarcinoma

2021 ◽  
Vol 22 (24) ◽  
pp. 13374
Author(s):  
Yen-Yu Lin ◽  
Yu-Chao Wang ◽  
Da-Wei Yeh ◽  
Chen-Yu Hung ◽  
Yi-Chen Yeh ◽  
...  
Keyword(s):  
Gene Expression ◽  
Brain Metastasis ◽  
Brain Metastases ◽  
Dna Sequencing ◽  
Lung Adenocarcinoma ◽  
Rna Sequencing ◽  
Cell Lines ◽  
Differentially Expressed Genes ◽  
Primary Tumor ◽  
The Brain

Lung adenocarcinoma has a strong propensity to metastasize to the brain. The brain metastases are difficult to treat and can cause significant morbidity and mortality. Identifying patients with increased risk of developing brain metastasis can assist medical decision-making, facilitating a closer surveillance or justifying a preventive treatment. We analyzed 27 lung adenocarcinoma patients who received a primary lung tumor resection and developed metastases within 5 years after the surgery. Among these patients, 16 developed brain metastases and 11 developed non-brain metastases only. We performed targeted DNA sequencing, RNA sequencing and immunohistochemistry to characterize the difference between the primary tumors. We also compared our findings to the published data of brain-tropic and non-brain-tropic lung adenocarcinoma cell lines. The results demonstrated that the targeted tumor DNA sequencing did not reveal a significant difference between the groups, but the RNA sequencing identified 390 differentially expressed genes. A gene expression signature including CDKN2A could identify 100% of brain-metastasizing tumors with a 91% specificity. However, when compared to the differentially expressed genes between brain-tropic and non-brain-tropic lung cancer cell lines, a different set of genes was shared between the patient data and the cell line data, which include many genes implicated in the cancer-glia/neuron interaction. Our findings indicate that it is possible to identify lung adenocarcinoma patients at the highest risk for brain metastasis by analyzing the primary tumor. Further investigation is required to elucidate the mechanism behind these associations and to identify potential treatment targets.

scholarly journals GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi111-vi111
Author(s):  
Naema Nayyar ◽  
David Shih ◽  
Ivanna Bihun ◽  
Ibiayi Dagogo-Jack ◽  
Corey Gill ◽  
...  
Keyword(s):  
Brain Metastasis ◽  
Brain Metastases ◽  
Lung Adenocarcinoma ◽  
Tumor Cells ◽  
Treatment Options ◽  
Control Cohort ◽  
Sequencing Data ◽  
Whole Exome Sequencing Data ◽  
Lung Adenocarcinomas ◽  
The Brain

Abstract Although lung adenocarcinomas frequently metastasize to the brain, treatment options for lung adenocarcinoma brain metastases are limited. We discovered novel candidate drivers of progression by using case-control analyses to compare whole-exome sequencing data from a cohort of 73 lung adenocarcinoma brain metastases to a control cohort of 503 primary lung adenocarcinomas. We identified 3 genomic regions with significantly more frequent amplifications in brain metastases compared to the control cohort: MYC (12% vs 6%), YAP1 (7% vs 0.8%) and MMP13 (10% vs 0.6%). We also identified CDKN2A/B as a region deleted at a significantly greater frequency in brain metastases compared to primary lung adenocarcinomas (27% vs 13%, respectively). We confirmed frequent amplifications of MYC and YAP1/MMP13 in an independent validation cohort of 105 lung adenocarcinoma brain metastasis samples using fluorescence in situ hybridization. We further validated that MYC, YAP1 and MMP13 can drive brain metastases in a patient-derived xenograft mouse model. We found a higher incidence of metastases to the brain in mice receiving intracardiac injections of tumor cells expressing the candidate drivers compared to tumor cells expressing LacZ as a control. These results indicate that somatic alterations can drive lung adenocarcinomas to metastasize to the brain. The candidate brain metastasis drivers that we identified may serve as therapeutic targets in patients with lung adenocarcinomas who develop this devastating complication.

scholarly journals Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma

Diagnostics ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 410 ◽  
Author(s):  
Rosa Fonti ◽  
Sara Pellegrino ◽  
Ciro Gabriele Mainolfi ◽  
Elide Matano ◽  
Silvana Del Vecchio
Keyword(s):  
Monoclonal Antibody ◽  
Brain Metastases ◽  
Fdg Pet ◽  
Palliative Therapy ◽  
Advanced Melanoma ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Brain

Recently, newer therapies such as immunotherapy have been increasingly used in the treatment of several tumors, including advanced melanoma. In particular, several studies showed that the combination of ipilimumab, an anti-Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) monoclonal antibody and nivolumab, an anti-Programmed Death 1 (PD-1) monoclonal antibody, leads to improved survival in patients with metastatic melanoma. Despite that, immunotherapeutic agents may not reach therapeutic concentration in the brain due to the blood–brain barrier. We report the case of a 50-year-old man with advanced melanoma who underwent whole-body 18F-FDG-PET/CT before and after treatment with immunotherapy showing resistant brain metastases confirmed by subsequent MRI of the brain. Moreover, 18F-FDG-PET/CT was able to detect an immune-related adverse event such as enterocolitis that contributed to the worsening of patient conditions. This case shows how a whole-body methodology such as 18F-FDG-PET/CT can be useful in identifying melanoma cancer patients unresponsive to immunotherapy that may benefit from traditional palliative therapy in the effort to improve their quality of life.

scholarly journals Significant Radiologic Response of Pancreatic Metastasis After Targeted Therapy of Ceritinib (LDK378) for ALK-Rearranged Lung Adenocarcinoma Presenting With Hyperglycemia

2017 ◽  
Vol 25 (4) ◽  
pp. 545-550 ◽  
Author(s):  
Jing Zheng ◽  
Jianya Zhou ◽  
Yanping Zhu ◽  
Qian Shen ◽  
Jianying Zhou
Keyword(s):  
Targeted Therapy ◽  
Lung Adenocarcinoma ◽  
Symptomatic Improvement ◽  
Pancreatic Metastasis ◽  
Small Cell Lung ◽  
Disease Free Interval ◽  
Pancreatic Metastases ◽  
Free Interval ◽  
The Brain ◽  
Disease Free

Pancreatic metastasis from non-small cell lung cancer (NSCLC) is usually asymptomatic or presents with abdominal pain, acute pancreatitis, or jaundice. A lung primary is associated with worse survival compared to pancreatic metastases from other organs. Surgical treatment of solitary metastasis to the pancreas from NSCLC has been reviewed in several studies, one of which had a notable disease-free interval. To our knowledge, there are no prior reports of targeted therapy of pancreatic metastasis of NSCLC followed by a significant response. Herein we report the case of a 31-year-old female with a solitary pancreatic metastasis from ALK-rearranged lung adenocarcinoma despite treatment with chemotherapy and crizotinib; she presented with symptoms of hyperglycemia. Targeted therapy with ceritinib (LDK378) led to symptomatic improvement and a significant radiologic response in the lung and pancreas, but not in the brain.

scholarly journals UNUSUAL METASTASES OF LUNG CANCER: BULBUS OCULI AND MAXILLARY SINUS

2015 ◽  
Vol 37 (3) ◽  
pp. 231-232 ◽  
Author(s):  
I Ates ◽  
O Yazici ◽  
H Ates ◽  
N Ozdemir ◽  
N Zengin
Keyword(s):  
Lung Cancer ◽  
Bone Marrow ◽  
Case Report ◽  
Parotid Gland ◽  
Lung Adenocarcinoma ◽  
Maxillary Sinus ◽  
Adrenal Glands ◽  
The Body ◽  
Unusual Metastases ◽  
The Brain

Lung adenocarcinoma often makes metastasis to the brain, liver, kidneys, bone, bone marrow and adrenal glands. It can also make metastasis to other parts of the body rarely for example eye, nose, parotid gland and paranasal sinus. We did not encounter with combined ocular bulbus and the maxillary sinus metastases of lung cancer in the accessible literature. In this case report, a patient who was combined ocular bulbus and the maxillary sinus metastases of lung adenocarcinoma will be discussed.

scholarly journals Lung Adenocarcinoma Isolated Metastasizing to Pancreas a Case Report and Review

2021 ◽  
Author(s):  
Ludong Tan ◽  
Yu Fu ◽  
Shupeg Wang ◽  
Jiang Peiqiang ◽  
Yahui Liu
Keyword(s):  
Lung Adenocarcinoma ◽  
Pancreatic Tumors ◽  
Pancreatic Metastasis ◽  
Pulmonary Lobectomy ◽  
Free Survival ◽  
Lung Cancers ◽  
Case Summary ◽  
Abdomen Ct ◽  
Pancreatic Neck ◽  
The Brain

Abstract BACKGROUND: Lung cancers are prone to metastasis. It is commonly associated with metastases in the brain, bone, and liver.However, isolated pancreatic metastasis are extremely rare in lung adenocarcinoma patients。CASE SUMMARY: A Chinese man underwent pulmonary lobectomy for adenocarcinrcinoma 6 years ago. He was referred to our department because that postoperative reexamination(Abdomen CT) revealed space occupying lesions in the pancreatic neck,and no abnormality was found in any other organ. Therefore, it was considered to pancreatic carcinoma. Pancreatectomy of the pancreatic body and tail, as well as splenectomy, were performed,and he was given four courses of Pemetrexed and Carboplatin chemotherapy after one month of operation. Then the gefitinib was given.A year after surgery, the patient survived without tumor.CONCLUSION: Secondary pancreatic tumors are rare in clinical practice.It is the longer tumor-free survival in patients with isolated pancreatic metastasis of lung adenocarcinoma.However,the value of surgical treatment for isolated metastasis of lung adenocarcinoma needs further discussion.

Sign in / Sign up

Export Citation Format

Share Document